Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
4.23 | -0.04 (-0.94%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 19,042 |
| Date : | 10-22-2018 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first [...]
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and [...]
Oramed to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]
Oramed Granted Japanese Patent for GLP-1 Analog Capsule
NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property [...]
Investors Tools